Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

To join this study, you would need to be at least 18 years old and have a type of lung cancer called non-small cell lung cancer that has spread. Doctors would also check that you are generally well enough to take part and have a life expectancy of at least three months.

You would not be able to join if you have a different type of lung cancer called small cell lung cancer, or if your cancer has certain specific genetic changes (like EGFR, ALK, ROS1, and BRAF V600E) for which other approved treatments are already available. You also cannot have had any previous treatment for your widespread lung cancer, or if your tumour is growing in a way that significantly increases the risk of serious bleeding.

If you decide to take part, you would be randomly assigned to one of two treatment groups – like flipping a coin, but done by a computer – to receive either ivonescimab or pembrolizumab, both combined with chemotherapy. Neither you nor your doctor would know which treatment you are receiving (this is called 'double-blind').

You would have regular hospital visits for your treatments and to have various tests and scans. These would include blood tests, physical examinations, and scans to see how the cancer is responding. These visits would continue for as long as you are receiving treatment. After finishing treatment, there would be follow-up appointments and tests to monitor your health and the cancer. The total length of your participation would depend on how your cancer responds to treatment.